Growth Metrics

Exagen (XGN) Operating Income (2018 - 2025)

Exagen (XGN) has disclosed Operating Income for 8 consecutive years, with -$5.0 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Operating Income fell 47.06% year-over-year to -$5.0 million, compared with a TTM value of -$14.1 million through Dec 2025, down 3.18%, and an annual FY2025 reading of -$14.1 million, down 3.18% over the prior year.
  • Operating Income was -$5.0 million for Q4 2025 at Exagen, down from -$3.1 million in the prior quarter.
  • Across five years, Operating Income topped out at -$2.6 million in Q2 2024 and bottomed at -$14.5 million in Q4 2022.
  • Average Operating Income over 5 years is -$6.0 million, with a median of -$5.1 million recorded in 2023.
  • The sharpest move saw Operating Income crashed 144.93% in 2022, then skyrocketed 65.05% in 2023.
  • Year by year, Operating Income stood at -$6.3 million in 2021, then plummeted by 131.71% to -$14.5 million in 2022, then surged by 64.48% to -$5.1 million in 2023, then soared by 34.27% to -$3.4 million in 2024, then crashed by 47.06% to -$5.0 million in 2025.
  • Business Quant data shows Operating Income for XGN at -$5.0 million in Q4 2025, -$3.1 million in Q3 2025, and -$2.6 million in Q2 2025.